1. Home
  2. METCB vs YMAB Comparison

METCB vs YMAB Comparison

Compare METCB & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • METCB
  • YMAB
  • Stock Information
  • Founded
  • METCB 2015
  • YMAB 2015
  • Country
  • METCB United States
  • YMAB United States
  • Employees
  • METCB N/A
  • YMAB N/A
  • Industry
  • METCB Coal Mining
  • YMAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • METCB Energy
  • YMAB Health Care
  • Exchange
  • METCB Nasdaq
  • YMAB Nasdaq
  • Market Cap
  • METCB 571.7M
  • YMAB 631.1M
  • IPO Year
  • METCB N/A
  • YMAB 2018
  • Fundamental
  • Price
  • METCB $9.88
  • YMAB $10.12
  • Analyst Decision
  • METCB Strong Buy
  • YMAB Strong Buy
  • Analyst Count
  • METCB 3
  • YMAB 9
  • Target Price
  • METCB $19.67
  • YMAB $21.56
  • AVG Volume (30 Days)
  • METCB 16.4K
  • YMAB 276.0K
  • Earning Date
  • METCB 11-04-2024
  • YMAB 11-08-2024
  • Dividend Yield
  • METCB 8.89%
  • YMAB N/A
  • EPS Growth
  • METCB N/A
  • YMAB N/A
  • EPS
  • METCB 0.71
  • YMAB N/A
  • Revenue
  • METCB $698,132,000.00
  • YMAB $84,553,000.00
  • Revenue This Year
  • METCB N/A
  • YMAB $10.24
  • Revenue Next Year
  • METCB $25.55
  • YMAB $20.21
  • P/E Ratio
  • METCB $18.72
  • YMAB N/A
  • Revenue Growth
  • METCB 11.52
  • YMAB N/A
  • 52 Week Low
  • METCB $9.42
  • YMAB $5.29
  • 52 Week High
  • METCB $16.77
  • YMAB $20.90
  • Technical
  • Relative Strength Index (RSI)
  • METCB 41.09
  • YMAB 23.39
  • Support Level
  • METCB $10.52
  • YMAB $12.47
  • Resistance Level
  • METCB $10.98
  • YMAB $11.11
  • Average True Range (ATR)
  • METCB 0.53
  • YMAB 1.02
  • MACD
  • METCB -0.06
  • YMAB -0.50
  • Stochastic Oscillator
  • METCB 13.90
  • YMAB 3.05

About METCB Ramaco Resources Inc. Class B

Ramaco Resources Inc is a United States-based company that operates as a pure-play metallurgical coal company with operations in southern West Virginia and southwestern Virginia. Its portfolio includes high-quality metallurgical coal reserves and resources, with a focus on properties such as Elk Creek, Berwind, Knox Creek, and Maben. These properties are strategically located to serve North American blast furnace steel mill and coke plants, as well as international metallurgical coal consumers. Additionally, the company controls mineral deposits in Sheridan, Wyoming, exploring potential opportunities in rare earth elements and coal-to-carbon-based products. Operations are concentrated in the Appalachian basin, with active mines at Elk Creek, Berwind, Knox Creek, and Maben mining complexes.

About YMAB Y-mAbs Therapeutics Inc.

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

Share on Social Networks: